[1] Zeng Q, Li N, Pan XF, et al.Clinical management and treatment of obesity in China[J].Lancet Diabetes Endo, 2021, 9(6): 393-405.
[2] 何耀.我国超重/肥胖流行趋势及其对公共卫生的挑战[J].中华流行病学杂志, 2014, 35(4): 4.
He Y.The epidemic trend of over weight/obesity in China and its challenge to public health[J].Chin J Epidemio, 2014, 35 (4): 4.(in Chinese)
[3] 国务院新闻办公室.《中国居民营养与慢性病状况报告(2020年)》国务院新闻办公室2020年12月23日新闻发布会(摘要)[J].营养学报,2020,42(6):521.
Information Office of the State Council.Report on nutrition and chronic diseases of Chinese residents (2020) press conference (abstract) of the state council information office on December 23, 2020[J].Journel of Nutrition,2020,42(6):521.(in Chinese)
[4] Chung A, Backholer K, Wong E, et al.Trends in child and adolescent obesity prevalence in economically advanced countries according to socioeconomic position: A systematic review[J].Obes Rev, 2016, 17(3): 276-295.
[5] NCD Risk Factor Collaboration(NCD-Risc)Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016:A pooled analysis of 2 416 population-based measurement studies in 128.9 million children, adolescents, and adults[J].Lancet, 2017, 390(10113): 2627-2642.
[6] Dejong KA, Czeczor JK, Sithara S, et al.Obesity and type 2 diabetes have additive effects on left ventricular remodelling in normotensive patients-a cross sectional study[J].Cardiovasc Diabetol, 2017, 16(1): 21.
[7] 李梅, 张晓蓉, 薛爱玲.超声心动图检测单纯性肥胖儿童心脏功能的改变[J].中国临床医生杂志, 2014,43(7):3.
Li M, Zhang XR, Xue AL.Detection of cardiac function changes in simple obese children by echocardiography[J].Chin J Clin, 2014,43(7):3.(in Chinese)
[8] Jing L, Nevius CD, Friday CM, et al.Ambulatory systolic blood pressure and obesity are independently associated with left ventricular hypertrophic remodeling in children[J].J Cardiovasc Magn Reson, 2017, 19(1): 86.
[9] Heiser D, Rubert J, Unterreiner A, et al.Evaluation of protein kinase D auto-phosphorylation as biomarker for NLRP3 inflammasome activation[J].PLoS One, 2021, 16(11): e0248668.
[10] Renton MC, Mcgee SL, Howlett KF.The role of protein kinase D (PKD) in intracellular nutrient sensing and regulation of adaptive responses to the obese environment[J].Obes Rev, 2021, 22(3): e13145.
[11] Lv D, Chen H, Feng Y, et al.Small-molecule inhibitor targeting protein kinase D:A potential therapeutic strategy[J].Front Oncol, 2021, 11: 680221.
[12] Steinberg SF.Decoding the cardiac actions of protein kinase D isoforms[J].Mol Pharmacol, 2021, 100(6): 558-567.
[13] Venardos K, Dejong KA, Elkamie M, et al.The PKD inhibitor CID755673 enhances cardiac function in diabetic db/db mice[J].PLoS One, 2015, 10(3): e0120934.
[14] Liu X, Xu Q, Wang X, et al.Irbesartan ameliorates diabetic cardiomyopathy by regulating protein kinase D and ER stress activation in a type 2 diabetes rat model[J].Pharmacol Res, 2015, 93: 43-51.
[15] Indoliya A, Pal K, Pattnaik AK, Poddar R.In vivo morphological study of obese development in mice model guided by swept-source optical coherence tomography (SSOCT).[J]. Biotech,2022,12(11):282.
[16] Jong K, Hall LG, Renton MC, et al.Loss of protein kinase D activity demonstrates redundancy in cardiac glucose metabolism and preserves cardiac function in obesity[J].Mol Metab, 2020, 42: 101-105.
[17] Zhang Y, Whaley-connell AT, Sowers JR, et al.Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management[J].Pharmacol Ther, 2018, 191: 1-22.
[18] Zhang Y, Sowers JR, Ren J.Targeting autophagy in obesity:From pathophysiology to management[J].Nat Rev Endocrinol, 2018, 14(6): 356-376.
[19] Virani SS, Alonso A, Benjamin EJ, et al.Heart disease and stroke statistics-2020 update:A report from the American heart association[J].Circulation, 2020, 141(9): e139-e596.
[20] Tong M, Saito T, Zhai P, et al.Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy[J].Circ Res, 2019, 124(9): 1360-1371.
[21] An M, Dong-Ryeol R, Jang WP, et al.ULK1 prevents cardiac dysfunction in obesity through autophagy-meditated regulation of lipid metabolism[J].Cardiovasc Res, 2017, 113(10): 1137.
[22] Li G, Li J, Shao R, et al.FUNDC1: A promising mitophagy regulator at the mitochondria-associated membrane for cardiovascular diseases[J].Front Cell Dev Biol, 2021, 9: 788634.
[23] Ren J, Sun M, Zhou H, et al.FUNDC1 interacts with FBXL2 to govern mitochondrial integrity and cardiac function through an IP3R3-dependent manner in obesity[J].Sci Adv, 2020, 6(38):eabc8561.
[24] Czech MP.Insulin action and resistance in obesity and type 2 diabetes[J].Nat Med, 2017, 23(7): 804-814.
[25] Chen F, Liu J, Hou D, et al.The relationship between fat mass percentage and glucose metabolism in children and adolescents: A systematic review and meta-analysis[J].Nutrients,2022,14(11):2272.
[26] Munoz MC, Piazza VG, Burghi V, et al.Insulin signaling in the heart is impaired by growth hormone: A direct and early event[J].J Mol Endocrinol, 2022, 69(2): 357-376.
[27] Lee J, Vijayakumar A, White PJ, et al.BCAA supplementation in mice with diet-induced obesity alters the metabolome without impairing glucose homeostasis[J].Endocrinology, 2021,162(7):bqab062.
[28] Wang W, Zhang F, Xia Y, et al.Defective branched chain amino acid catabolism contributes to cardiac dysfunction and remodeling following myocardial infarction[J].Am J Physiol Heart Circ Physiol, 2016, 311(5): H1160-h9.
[29] Kroemer G, Loper-Otin C, Madeo F, et al.Carbotoxicity-noxious effects of carbohydrates[J].Cell, 2018, 175(3): 605-614.
[30] Mcnay EC, Pearson-leary J.GluT4: a central player in hippocampal memory and brain insulin resistance[J].Exp Neurol, 2020, 323: 113076.
[31] Bertrand L, Auquier J, Renguet E, et al.Glucose transporters in cardiovascular system in health and disease[J].Pflugers Arch, 2020, 472(9): 1385-1399.
[32] Seidelmann SB, Feofanova BE, Yu CB, et al.Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk[J].J Am Coll of Cardiol, 2018, 72(15): 1763-1773.
[33] Rayner JJ, Banerjee R, Holloway CJ, et al.Correction: the relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity[J].Int J Obes (Lond), 2019, 43(8): 1652.
[34] Zhang L, Ussher JR, Oka T, et al.Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation[J].Cardiovasc Res, 2011, 89(1): 148-156.
[35] Nakamura M, Liu T, Husain S, et al.Glycogen synthase kinase-3α promotes fatty acid uptake and lipotoxic cardiomyopathy[J].Cell Metab, 2019, 29(5): 1119-1134,e12.
[36] Costantino S, Akhmedov A, Melina G, et al.Obesity-induced activation of Jund promotes myocardial lipid accumulation and metabolic cardiomyopathy[J].Eur Heart J, 2019, 40(12): 997-1008.
[37] Rossi A, Pizzo P, Filadi R.Calcium, mitochondria and cell metabolism: A functional triangle in bioenergetics[J].Biochim Biophys Acta Mol Cell Res, 2019, 1866(7): 1068-1078.
[38] Xu HX, Cui SM, Zhang YM, et al.Mitochondrial Ca(2⁺) regulation in the etiology of heart failure: Physiological and pathophysiological implications[J].Acta Pharmacol Sin, 2020, 41(10): 1301-1309.
[39] Goodman JB, Qin F, Morgan RJ, et al.Redox-resistant SERCA [sarco(endo)plasmic reticulum calcium ATPase] attenuates oxidant-stimulated mitochondrial calcium and apoptosis in cardiac myocytes and pressure overload-induced myocardial failure in mice[J].Circulation, 2020, 142(25): 2459-2569.
[40] Gorski PA, Jang SP, Jeong D, et al.Role of SIRT1 in modulating acetylation of the sarco-endoplasmic reticulum Ca(2+)-ATPase in heart failure[J].Circ Res, 2019, 124(9): e63-e80.
[41] Mazeto FS, Okoshi K, Silveira C, et al.Calcium homeostasis behavior and cardiac function on left ventricular remodeling by pressure overload[J].Braz J Med Biol Res, 2021, 54(4): e10138.
[42] Bartoli F, Bailey MA, Rode B, et al.Orai1 channel inhibition preserves left ventricular systolic function and normal Ca²⁺ handling after pressure overload[J].Circulation, 2020,141(3):199-216.
[43] Hegyi B, Bers DM, Bossuyt J.CaMKII signaling in heart diseases: Emerging role in diabetic cardiomyopathy[J].J Mol Cell Cardiol, 2019, 127: 246-259.
[44] Zhong P, Quan D, Peng J, et al.Corrigendum to “Role of CaMKII in free fatty acid/hyperlipidemia-induced cardiac remodeling both in vitro and in vivo”[J].J Mol Cell Cardiol, 2018, 121: 306.
[45] Ren J, Wu NN, Wang S, et al.Obesity cardiomyopathy: evidence, mechanisms and therapeutic implications[J].Physiol Rev, 2021,101(4):1745-1807.
[46] Thoudam T, Ha CM, Leem J, et al.PDK4 augments ER-Mitochondria contact to dampen skeletal muscle insulin signaling during obesity[J].Diabetes, 2019, 68(3): 571-586.